Overview

Surufatinib Renal Impairment Study

Status:
Completed

Trial end date:
2021-08-21

Target enrollment:

Participant gender:

Summary

An open-label, multicenter, single-dose, single-period, sequential study to assess the effect of moderate renal impairment on the pharmacokinetics of surufatinib.

Phase:

Phase 1

Details

Lead Sponsor:

Hutchison Medipharma Limited